Indalo Therapeutics is a technology company.
Indalo Therapeutics has raised $9.0M across 1 funding round.
Indalo Therapeutics has raised $9.0M in total across 1 funding round.
Indalo Therapeutics has raised $9.0M in total across 1 funding round.
Indalo Therapeutics's investors include Andera Partners, Atlas Venture, Bain Capital Life Sciences, F-Prime Capital Partners, HealthCap.
Indalo Therapeutics is a preclinical-stage biotechnology company headquartered in St. Louis, Missouri, focused on developing novel small-molecule therapies for fibrotic diseases, such as renal, hepatic, pulmonary, pancreatic, muscular, and surgical implant fibrosis.[1][2][3] It targets integrins—key proteins in fibrotic responses—with orally bioavailable compounds showing strong preclinical activity, addressing a critical unmet need in treating debilitating conditions like nonalcoholic steatohepatitis (NASH).[2][5] The company serves patients with fibrotic disorders, backed by an experienced team, strong intellectual property, and a robust drug portfolio; it raised $9 million in 2017 toward a $26 million equity round from investors including BioGenerator and iSelect Fund, with F-Prime Capital as an early backer.[1][2]
Indalo Therapeutics emerged in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics, combining their complementary assets in anti-fibrotic drug development.[2] This union created a company with a diverse IP estate and expertise in integrin-targeted small molecules, as highlighted by chairman Rajesh Devraj, who noted its potential to tackle complex fibrosis challenges.[2] Some sources reference roots as early as 2014, but the formal entity formed post-merger with initial investment in 2017 from F-Prime Capital.[1][4] Early traction included a strong preclinical portfolio demonstrating efficacy across multiple fibrosis models.[1][2]
Indalo rides the wave of fibrosis therapy innovation, a high-unmet-need area where few treatments exist despite fibrosis contributing to millions of deaths annually from organ failure.[2] Timing aligns with advances in integrin biology and growing interest from big pharma like Roche, Allergan, and Bristol-Myers Squibb, amid a competitive field including Promedior, Pliant Therapeutics, and Galectin Therapeutics.[2] Market forces favor Indalo through its merged IP and preclinical momentum, enabling efficient progression to clinical stages like Phase 2 for NASH—a lucrative indication amid rising liver disease prevalence.[2][5] It influences the St. Louis biotech ecosystem as a BioGenerator-backed firm, fostering regional life sciences growth.[2]
Indalo's path forward hinges on advancing IDL-2965 and pipeline candidates through clinical milestones, potentially attracting partnerships or buyouts in the consolidating fibrosis space.[2][5] Trends like precision targeting of integrins and NASH market expansion (projected to exceed $50B by 2030) could propel growth, especially if preclinical breadth translates to human efficacy.[2] Its influence may evolve from preclinical innovator to clinical leader or acquisition target, reinforcing biotech's focus on hard-to-treat fibrotic diseases—echoing its origins as a merger-built powerhouse tackling fibrosis head-on.[1][2]
Indalo Therapeutics has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Venture Round in August 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2017 | $9.0M Venture Round | Andera Partners, Atlas Venture, Bain Capital Life Sciences, F-Prime Capital Partners, HealthCap |